(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a renal cell cancer rapid oral abstract session. Dr. Frankie Jackson-Spence presented the final overall survival and new ctDNA analysis from CALYPSO in MET-driven advanced papillary renal cancer.
Metastatic papillary renal cancer has poor outcomes, and new treatments are needed. There is a strong rationale for investigating the combination of mesenchymal epithelial transition receptor (MET) and programmed cell death ligand-1 (PD-L1) inhibitors in this disease.
CALYPSO is a phase II study investigating savolitinib (600 mg once daily) + durvalumab (1,500 mg every four weeks) in advanced papillary RCC patients. Treatment-naïve or previously…